source
- Sanofi eyes late-stage and commercial acquisitions to counter upcoming Dupixent revenue dropSanofi said on its third‑quarter earnings call that it is looking to acquire late‑stage and commercial medicines to sustain growth after Dupixent loses exclusivity. CEO Belén Garijo highlighted th…
- Sanofi says no major restructuring despite upcoming Dupixent patent expirationSanofi's new chief executive, Belén Garijo, said after six months in charge that the company will not embark on a major overhaul of its business or research pipeline. The comment was made as the b…